Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Antengene Starts Dose Expansion in Trial of Claudin 18.2 ADC

publication date: Mar 20, 2024

Shanghai Antengene has started the dose expansion portion of a China/Australia Phase II trial of ATG-022, a Claudin 18.2 antibody-drug conjugate. The trial, which is already underway, enrolled patients who have advanced or metastatic solid tumors, some of whom have experienced partial or complete responses. The study’s primary goal is to evaluate the safety and tolerability of ATG-022 and to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of ATG-022 as a monotherapy. The US FDA has granted two Orphan Drug Designations for ATG-022, one for gastric cancer and the another for pancreatic cancer. More details....

Stock Symbols: (HK: 6996)

Share this with colleagues: